What type of drug is greffitumab?

Glofitamab (Glofitamab) is a new type of bispecific T-cell Engager (BiTE), mainly used to treat relapsed or refractory large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma) and other B-cell-related malignant tumors. This drug is different from traditional monoclonal antibody drugs. Its mechanism is based on targeting CD20 and CD3 molecules at the same time. CD20 is a B cell surface antigen, while CD3 exists on the surface of T cells. Through these two specific combinations, gaffetuzumab can directly recruit T cells in the patient's body to malignant B cells, thereby activating T cells to attack and kill tumor cells.

The unique structural design of gerfitomab enables it to possess strong immune-mediated cytotoxicity (T-cell mediated cytotoxicity) in terms of pharmacological functions. Compared with conventional anti-CD20 monoclonal antibodies (such as rituximab and obinutuzumab), it does not only rely on antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), but uses a more active "bridging" mechanism to promote the establishment of immune synapses between T cells and target cells in the body, greatly enhancing the anti-tumor effect. Therefore, gaffetuzumab is often classified as a "dual antibody" drug and is one of the cutting-edge technologies in immuno-oncology treatment.

Currently, gaffetuzumab has received certain clinical approval in Europe and the United States and other countries for the treatment of specific types of lymphoma, especially providing a new immunotherapy option for patients who have failed other therapies. This drug embodies the trend of combining medicine and immunotherapy, and its development direction represents the strategic thinking of the dual mechanism of "precision targeting + immune activation" in future cancer treatment. The research and development of gaffetuzumab has also promoted technological innovation in the field of bispecific antibodies, providing treatment hope for more refractory hematological tumors.

Reference materials:https://www.drugs.com/glofitamab.html